Robert H. Hyland

Gilead Sciences (United States) — United States

Medicine · Health Sciences

54h-index19.9kcitations173works3.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatitis C virus research(69), Liver Disease Diagnosis and Treatment(33), Hepatitis B Virus Studies(29), HIV/AIDS drug development and treatment(28), COVID-19 Clinical Research Studies(16)

Publications173 total

Efficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled study
The Lancet Infectious Diseases·2025· 6 citedOpen Access
P-2031. Thorough QT/QTc Clinical Study to Evaluate the Effect of Remdesivir on Cardiac Repolarization in Healthy Participants
Open Forum Infectious Diseases·2025· 1 citedOpen Access
P-2026. Obeldesivir for the Treatment of COVID-19 in People with Risk Factors for Progression to Severe Disease: the BIRCH Study
Open Forum Infectious Diseases·2025· 1 citedOpen Access
P-2036. Obeldesivir for Treatment of COVID-19 in Adults and Adolescents Without Risk Factors for Progression to Severe Disease: the OAKTREE Study
Open Forum Infectious Diseases·2025· 1 citedOpen Access
92. Obeldesivir Reduced SARS-CoV-2 Infectious Titers in the BIRCH Phase 3 Clinical Trial
Open Forum Infectious Diseases·2025· 1 citedOpen Access
Clinical Pharmacokinetics and Safety of Remdesivir in Phase I Participants with Varying Degrees of Renal Impairment
Clinical Pharmacokinetics·2024· 1 cited
Efficacy and Safety of Remdesivir in People With Impaired Kidney Function Hospitalized for COVID-19 Pneumonia: A Randomized Clinical Trial
Clinical Infectious Diseases·2024· 13 citedOpen Access
506. Resistance Analyses from the Remdesivir Phase 3 REDPINE Study in Participants with Severely Reduced Kidney Function Who Were Hospitalized for COVID-19
Open Forum Infectious Diseases·2023· 1 citedOpen Access
539. Efficacy in Multiple SARS-CoV-2 Animal Models Supports Phase 3 Dose Selection for Obeldesivir
Open Forum Infectious Diseases·2023· 3 citedOpen Access
538. Clinical Evaluation of Drug-drug Interactions with Remdesivir
Open Forum Infectious Diseases·2023· 1 citedOpen Access
524. Hepatic Safety of Remdesivir Across Phase 3 Placebo-controlled COVID-19 Studies
Open Forum Infectious Diseases·2023Open Access
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection
New England Journal of Medicine·2022· 270 citedOpen Access
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
New England Journal of Medicine·2021· 1.2k citedOpen Access
LB1. Remdesivir for the Treatment of High-Risk Non-Hospitalized Individuals With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial
Open Forum Infectious Diseases·2021· 8 citedOpen Access
Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease
The American Journal of Gastroenterology·2021· 10 citedOpen Access
548. Baseline characteristics associated with clinical improvement and mortality in hospitalized patients with moderate COVID-19
Open Forum Infectious Diseases·2020· 3 citedOpen Access
561. Safety of Remdesivir vs Standard Care in Patients with Moderate Covid-19
Open Forum Infectious Diseases·2020· 5 citedOpen Access
557. Impact of Concomitant Hydroxychloroquine Use on Safety and Efficacy of Remdesivir in Moderate COVID-19 Patients
Open Forum Infectious Diseases·2020· 3 citedOpen Access
72. Remdesivir vs Standard Care in Patients with Moderate covid-19
Open Forum Infectious Diseases·2020· 2 citedOpen Access
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19
JAMA·2020· 1.3k citedOpen Access
page 1 of 9Next →

Frequent Co-authors

Diana M. Brainard(16), John G. McHutchison(15), William T. Symonds(12), Hadas Dvory‐Sobol(12), Evguenia S. Svarovskaia(11), Edward Gane(10), Eric Lawitz(8), G. Mani Subramanian(8), Marie E. Faughnan(7), Phillip S. Pang(7), K. Rajender Reddy(6), Kris V. Kowdley(6), Catherine Stedman(6), Stuart C. Gordon(5), Di An(5), Marc Bourlière(5), Luisa M. Stamm(5), Hongmei Mo(5), Ira M. Jacobson(4), Anu Osinusi(4)